16-BRE-49-MK A Randomized, Double-Blind, Phase III Study of Pembrolizumab (MK-3475) plus Chemotherapy vs Placebo plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer(KEYNOTE-355)

  • Mathew, Aju (PI)

Grants and Contracts Details

StatusFinished
Effective start/end date7/1/1611/30/16